Cardiometabolic Care: Managing Health Risks From Obesity

Cardiometabolic care for obesity is crucial for health. Find effective methods to tackle obesity and enhance your vitality.

Educational Abstract: Integrative Care Pathways for Insulin Resistance, PCOS, Binge Eating, and Cardiometabolic Risk

In this comprehensive educational post, I, Dr. Alex Jimenez, present a detailed, first-person exploration of modern, evidence-based approaches to metabolic health and obesity care. This document is designed to unify internal medicine, chiropractic care, functional medicine, and rehabilitative strategies within a cohesive, multidisciplinary framework. Drawing directly from the latest findings of leading researchers and utilizing robust, evidence-based methods, I map how insulin resistance, Polycystic Ovary Syndrome (PCOS), dyslipidemia, prediabetes, sarcopenia, and binge eating behaviors intersect with systemic inflammation, autonomic nervous system imbalance, and musculoskeletal load.

I will explain the deep physiological underpinnings behind every clinical decision and technique we employ. Furthermore, I will highlight exactly how our highly integrated team functions at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Here, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933) serves as our Medical Director and Collaborative Physician alongside me. Together, we demonstrate an approach anchored in advanced metabolic diagnostics, functional nutrition, chiropractic neuromechanics, and targeted neuromusculoskeletal rehabilitation. By walking step-by-step through five distinct and complex clinical case studies—Eloise, George, Lynn, Amit, and Dolores—I will illustrate our protocols for assessment, risk stratification, hormone optimization, pharmacology (including metformin, tirzepatide, and semaglutide), and therapeutic sequencing. Ultimately, this post synthesizes rigorous science with compassionate patient care, providing a blueprint for long-term health restoration.

About Our Integrative Clinic and Collaborative Medical Team

Over my decades in clinical practice, my life’s work has been dedicated to bridging the gaps between structural alignment, systemic health, and advanced metabolic function. As a practitioner holding dual licensure and advanced certifications—Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner (FNP-BC), and certified in functional and lifestyle medicine (CFMP, IFMCP, ATN, CCST)—I view the human body through multiple intersecting lenses.

However, addressing the profound complexities of chronic metabolic disease, cardiovascular risk, and severe musculoskeletal injury requires a robust team. At Injury Medical Clinic PA in El Paso, Texas, we operate on a highly synergistic multidisciplinary model. This setup is common in the most advanced integrative and injury care centers, where medical direction aligns flawlessly with functional and physical medicine.

Dr. Maria Guadalupe Cardenas, MD, anchors our team. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of profound clinical experience as an internist to her role as our Medical Director and Collaborative Physician. Her oversight is the medical backbone of our practice. She directs all complex medical diagnostics, precise pharmacotherapy, medication safety protocols, intensive laboratory monitoring, and overall coordination of cardiometabolic care.

My role within this collaborative structure focuses intensely on:

• Functional Medicine Assessments: Investigating the root causes of disease by evaluating hormonal cascades, inflammatory markers, gut microbiome integrity, and lifestyle triggers.
• Integrative Chiropractic Care and Neuromechanics: Delivering precise interventions for spinal, pelvic, and kinetic chain alignment. This facilitates pain-free movement, normalizes joint kinematics, and optimizes autonomic nervous system balance.
• Rehabilitation Programming: Designing graded physical activity and biomechanical restoration plans to rebuild lean muscle mass and stabilize joint function.
• Co-Management of Complex Cases: Working hand-in-hand with Dr. Cardenas to ensure the safe integration of medical interventions, such as GLP-1/GIP receptor agonists and insulin-sensitizing agents, alongside physical rehabilitation.

Our extended clinical ecosystem also includes registered dietitians for medically supervised nutrition therapy, physical therapists, behavioral health practitioners for psychological support, and personal injury care coordinators. This integration guarantees that our patients receive unparalleled medical precision wrapped in functional systems thinking.

Rethinking the Stigma of Obesity: Chemical Versus Character

Before we explore our clinical pathways, we must completely dismantle the pervasive and damaging narrative surrounding obesity. I constantly encounter patients who feel a deep sense of shame regarding their appetite or weight history. They have been taught by society, and often by the medical establishment, that overwhelming hunger is a moral failure or a lack of willpower.

I am here to emphatically state that this is an issue of neurobiology, not character. Obesity is a highly complex, heterogeneous chronic disease. As visceral adipose tissue (VAT) expands, it ceases to be just a storage depot for excess calories; it becomes a highly active, pathogenic endocrine organ. Excess VAT secretes pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6), which actively interfere with insulin signaling at the cellular level, specifically disrupting GLUT4 transporter translocation. This creates insulin resistance.

Furthermore, hormonal signaling becomes profoundly deranged. Leptin, the satiety hormone produced by fat cells, becomes elevated, but the brain develops leptin resistance, rendering the individual constantly hungry despite having ample energy stores. Ghrelin, the hunger hormone secreted by the stomach, loses its normal pulsatile rhythm. Endogenous Glucagon-Like Peptide-1 (GLP-1), which normally signals the brain that we are full, becomes blunted. Adiposity also increases the activity of the enzyme aromatase, which converts androgens into estrogens, drastically altering reproductive hormones in both men and women.

This creates a self-perpetuating positive feedback loop: adiposity drives hormonal dysregulation and inflammation, which in turn drives unyielding hunger and further fat storage. By explaining this “chemical versus character” framework to my patients, we instantly remove the stigma. Shame is a terrible long-term motivator and an ineffective treatment. Compassionate, evidence-based neurobiology is the cure.

Case Study 1: The Integrative Pathway for PCOS, Insulin Resistance, and Binge Eating

To understand how our integrative model functions, let us look at Eloise, a 25-year-old fitness director. Despite being highly active, she presented in early 2026 with a long-standing history of weight cycling, irregular and infrequent menses, cystic acne, and a Body Mass Index (BMI) of 37.5.

Patient Presentation and Diagnostic Synthesis

Eloise was locked in a cycle of severe calorie anxiety. She would restrict her intake to 1200 kcal/day, triggering intense physiological hunger that resulted in binge eating episodes 1-2 times per week. She engaged in cardio and yoga up to six times a week but saw no changes. She desired future pregnancy but had been sexually active for five years without contraception and no conception.

Dr. Cardenas and I ordered a comprehensive metabolic and hormonal panel. The findings were revealing:

• Fasting Insulin:1 µU/mL (indicating severe hyperinsulinemia; optimal is under 6).
• Fasting Glucose: 107 mg/dL (impaired fasting glucose).
• HOMA-IR:5 (profound insulin resistance).
• Hemoglobin A1c (HbA1c):0% (prediabetes).
• Lipid Panel: High triglycerides, low HDL, elevated small dense LDL particles.

Clinically, Eloise met the Rotterdam criteria for Polycystic Ovary Syndrome (PCOS), exhibiting both hyperandrogenism (cystic acne, mild hirsutism) and ovulatory dysfunction. She also exhibited physical markers of insulin resistance, including acanthosis nigricans (darkened skin patches) and skin tags.

The Physiological Underpinnings of PCOS and Binge Eating

Why do these findings matter? Hyperinsulinemia is the primary driver of Eloise’s condition. High circulating insulin stimulates the ovaries to produce excess testosterone, driving her acne and preventing normal follicle maturation and ovulation. Furthermore, insulin resistance increases hepatic de novo lipogenesis (the liver converting excess carbohydrates into fat), leading to her dyslipidemia pattern.

From a neurological standpoint, Eloise’s binge eating disorder (BED) is deeply intertwined with her glycemic volatility. Restrictive eating plummets blood glucose, causing a surge in cortisol and adrenaline. The brain’s survival mechanisms override her prefrontal cortex, driving her toward highly palatable, energy-dense foods to rapidly restore blood sugar.

From an integrative chiropractic perspective, her Class II obesity and central adiposity shifted her center of mass anteriorly. This placed immense biomechanical stress on her lumbar facet joints and sacroiliac ligaments, creating a constant hum of nociceptive (pain) input. This chronic pain signaling maintains the nervous system in a state of sympathetic overdrive (fight-or-flight), which directly impairs digestion, sleep, and insulin sensitivity.

Multidisciplinary Treatment Plan and Pharmacotherapy

Dr. Cardenas provided the medical safety parameters for our intervention. We immediately targeted her insulin resistance to save her ovulatory function and metabolic future.

1. Pharmacology: Cardenas prescribed Metformin ER, titrating up to 2000 mg daily. Metformin suppresses hepatic gluconeogenesis and improves peripheral tissue insulin sensitivity. Next, to stabilize her neurobiological appetite drive, we initiated Tirzepatide, a dual GIP and GLP-1 receptor agonist. By mimicking these incretin hormones, Tirzepatide delays gastric emptying, profoundly enhances satiety, and corrects the glucose-dependent insulin response.
2. Contraception Planning: Because Tirzepatide causes delayed gastric emptying, it can reduce the absorption and efficacy of oral contraceptives. Dr. Cardenas provided strict counseling to use a barrier method during the first four weeks of therapy and after any dose escalation to prevent an unintended, high-risk pregnancy during active weight reduction.
3. Nutrition and Behavior: Rather than counting calories, we shifted her to a reduced-carbohydrate, high-protein pattern (90-100 grams of protein daily, 50-100 grams of fiber). Eating every 3-4 hours stabilized her blood sugar, eliminating the physiological trigger for her binge eating.
4. Integrative Chiropractic Care: I treated Eloise with specific spinal and pelvic neuromechanical adjustments to optimize her lumbopelvic rhythm. Furthermore, I utilized diaphragm retraining and rib cage mobilization. By improving respiratory efficiency, we actively stimulated the vagus nerve, shifting her autonomic nervous system into a parasympathetic (rest-and-digest) dominant state. This reduction in sympathetic tone directly lowers cortisol, further aiding her glycemic stability.

Outcomes at Two Years

By mid-2026, roughly two years into her care, Eloise’s transformation was astounding. She achieved a 24.1% total body weight reduction. Her fasting insulin plummeted to 8.4 µU/mL, and her HbA1c normalized to 5.2%. With her insulin resistance resolved, her endogenous testosterone levels dropped, her acne cleared, and her natural menstrual cycle returned. The binge eating behaviors completely vanished, replaced by a peaceful relationship with food. Through the synergy of Dr. Cardenas’s medical management and my functional chiropractic care, we mitigated her risk for type 2 diabetes and fully restored her fertility potential.

Case Study 2: Reversing Cardiometabolic Risk and Restoring Male Fertility

Our multidisciplinary model is equally vital for men’s health. Consider George, a 35-year-old project manager seeking care because he and his spouse were struggling to conceive their second child. George had been diagnosed with low sperm count, elevated blood pressure, and presented with intense work-related stress, poor sleep, and significant weight gain.

Diagnostic Evaluation and the Role of Aromatase

George’s lab results revealed a fasting insulin indicating resistance (HOMA-IR of 3.1), prediabetes (A1c 5.9%), and systemic dyslipidemia. His blood pressure was consistently hypertensive. He reported feeling ashamed that he could not control his appetite and was heavily relying on hyper-palatable office snacks.

To help George, I had to explain the deep physiology linking his weight, his blood pressure, and his fertility. Visceral fat is loaded with the enzyme aromatase. In men, aromatase actively steals testosterone and converts it into estradiol (estrogen). This hormonal inversion suppresses the hypothalamus-pituitary-gonadal axis, leading to reduced spermatogenesis, lowered libido, and occasional erectile dysfunction.

Simultaneously, his sleep debt and chronic stress kept his cortisol elevated. Cortisol upregulates gluconeogenesis in the liver, dumping sugar into the bloodstream, which forces the pancreas to pump out more insulin. This hyperinsulinemia blunts leptin signaling, leaving him ravenously hungry. Furthermore, inflammatory adipokines released by his visceral fat impaired the endothelial function of his blood vessels, reducing nitric oxide availability and driving his hypertension.

Integrative Intervention: CPAP, Semaglutide, and Nervous System Regulation

Our approach for George was heavily integrated:

1. Medical Oversight: Cardenas immediately initiated an antihypertensive medication to protect his cardiovascular system. We also referred him for a sleep study, which confirmed Obstructive Sleep Apnea (OSA). He was fitted for a CPAP machine. Resolving nocturnal hypoxemia is mandatory for restoring insulin sensitivity and lowering sympathetic nerve activity.
2. Appetite Modulation: To combat his relentless hunger, we discussed using a GLP-1 receptor agonist. Under Dr. Cardenas’s guidance, George started Semaglutide, titrating slowly to a maintenance dose of 1.7 mg weekly. By acting on the hypothalamus, Semaglutide replaced his blunted endogenous satiety signals, quieting the “food noise” and allowing him to make conscious nutritional choices. We also temporarily utilized bupropion to support his mood, motivation, and depressive symptoms associated with chronic stress.
3. Chiropractic and Functional Movement: George’s long commute had resulted in severe gluteal amnesia and lumbar stiffness, making exercise painful. My role was to utilize targeted chiropractic adjustments to restore pelvic biomechanics and hip mobility. We implemented “movement micro-doses”—short, 10-minute walks throughout the workday. These brief bouts of low-intensity exercise activate AMPK pathways in skeletal muscle, forcing the muscles to take up glucose independently of insulin, rapidly lowering his blood sugar.
4. Stress Reframing: We introduced micro-meditation practices (3 minutes in his car before entering the house) to sever the connection between workday stress and evening emotional eating.

One year later, George’s HOMA-IR had normalized to 1.64. He reversed his prediabetes. His blood pressure was perfectly controlled. His waist circumference shrank drastically, meaning the aromatase activity in his visceral fat was vastly reduced. Consequently, his testosterone rebounded, his sperm count recovered, and he joyfully reported that his spouse was expecting a baby girl.

For more insights into my clinical observations regarding autonomic regulation and male metabolic health, please visit https://chiropracticscientist.com/ and my professional network at https://www.linkedin.com/in/dralexjimenez/.

Case Study 3: Navigating Perimenopause, Hormonal Shifts, and Weight Gain

The hormonal transition of perimenopause presents unique metabolic challenges that require highly nuanced care. Lynn, a 43-year-old event planner, sought our help for debilitating brain fog, insomnia, severe mood swings, hot flashes, and a rapid, unexplained 20-pound weight gain localized around her abdomen. She also presented with Stage 1 Hypertension and an A1c of 5.7% (prediabetes).

The Physiology of the Perimenopausal Transition

Lynn felt betrayed by her body. Despite no changes to her diet, her waistline was expanding. I explained the profound physiological shifts occurring within her. As ovarian function fluctuates during perimenopause, estrogen and progesterone levels become erratic before ultimately declining.

Estrogen is highly protective of metabolic function. It promotes subcutaneous fat storage (around the hips and thighs) and enhances insulin sensitivity. As estrogen drops, fat storage shifts toward the highly inflammatory visceral adipose tissue compartment. This central adiposity rapidly accelerates insulin resistance. Furthermore, the loss of estrogen destabilizes the hypothalamic thermoregulatory center, causing vasomotor symptoms (hot flashes), which profoundly disrupt sleep architecture. Fragmented sleep spikes cortisol, driving morning hyperglycemia and daytime sugar cravings.

The Decision Matrix: Hormone Therapy vs. Obesity Medication

Our clinical decision-making here perfectly illustrates the power of an integrative team. Should we treat the obesity first, or the hormonal imbalance? Through shared decision-making with Dr. Cardenas, we prioritized the root cause of her systemic distress: the hormonal collapse.

1. Menopausal Hormone Therapy (MHT): Cardenas initiated transdermal estradiol alongside oral progesterone (to protect her intact uterus). We chose the transdermal route because it bypasses first-pass liver metabolism, significantly lowering the risk of venous thromboembolism compared to oral estrogens. Within six weeks, Lynn’s hot flashes ceased, her sleep was restored, and her brain fog lifted.
2. Introducing Tirzepatide: With her nervous system stabilized by the MHT and her sleep restored, we introduced Tirzepatide to address her insulin resistance and central adiposity. The dual GIP/GLP-1 action provided a synergistic effect, lowering her prediabetic blood sugars and facilitating the loss of visceral fat.
3. Preserving Muscle Mass: A critical danger of rapid weight loss in perimenopausal women is the exacerbation of age-related muscle loss. We rigorously monitored her body composition. I prescribed specific resistance training protocols and our dietitians ensured a daily protein intake of 90-100 grams to maximize muscle protein synthesis.
4. Chiropractic Integration: As Lynn began a new strength training regimen, she experienced cervical and thoracic stiffness. My chiropractic interventions focused on mobilizing the thoracic spine and rib cage. This not only relieved her musculoskeletal pain but improved her respiratory mechanics, supporting deeper, restorative sleep patterns.

Three years later, at age 46, Lynn remains on a maintenance dose of MHT and Tirzepatide. Her weight has stabilized at a healthy baseline, her blood pressure is normal, and she is thriving with renewed energy and physical strength.

Transform Your Body!- Video

Case Study 4: Sarcopenic Obesity, Type 2 Diabetes, and Cardiovascular Rehabilitation

To understand the extremes of metabolic disease, we must examine Amit, a 57-year-old factory manager. Amit’s history was a cascade of advanced pathology: a prior myocardial infarction (heart attack), Stage 2A Peripheral Artery Disease (PAD) causing claudication, Type 2 Diabetes managed with high doses of both basal and bolus insulin, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Diagnosing Sarcopenic Obesity and the Danger of Exogenous Insulin

Amit’s BMI was 38.4 (Class 2 Obesity). However, a deeper look via body composition analysis revealed the true severity of his state. His body fat was an astonishing 56.7%, while his skeletal muscle mass was critically depleted, placing him in the 4th percentile for his age. This is the definition of sarcopenic obesity—a highly dangerous phenotype combining the inflammatory burden of massive adiposity with the frailty and metabolic impairment of severe muscle wasting.

Furthermore, Amit was caught in an iatrogenic (medically induced) trap. He was taking massive amounts of exogenous insulin to control his blood sugar. However, insulin is the body’s ultimate fat-storage hormone. It actively promotes adipogenesis and strictly inhibits lipolysis (fat burning). Prescribing high-dose insulin to a severely obese, highly insulin-resistant patient is akin to pouring gasoline on a fire; it forces blood sugar into fat cells, driving relentless weight gain and worsening the underlying cardiovascular disease.

A Stepwise Approach: Semaglutide, Deprescribing, and Biomechanics

Our treatment required extreme medical vigilance provided by Dr. Cardenas, paired with aggressive physical rehabilitation.

1. Semaglutide for Cardiovascular Protection: We immediately initiated Semaglutide. Beyond weight loss, we chose this specifically based on the landmark SELECT trial, which demonstrated that Semaglutide significantly reduces the risk of major adverse cardiovascular events in patients with established cardiovascular disease and obesity. It was the perfect pharmacological tool to protect his heart while treating his metabolism.
2. Deprescribing Insulin: As the Semaglutide restored his endogenous insulin sensitivity and suppressed his glucagon levels, Dr. Cardenas meticulously and progressively tapered his exogenous insulin. Within six months, he was entirely off injectable insulin. This halted the massive chemical drive for fat storage, allowing true metabolic healing to begin.
3. Nutritional Strategy: We implemented a high-protein Mediterranean diet. Because type 2 diabetes is essentially a state of severe carbohydrate intolerance, we drastically reduced his exposure to refined starches and sugars.
4. Chiropractic and Physical Therapy Integration: Amit’s PAD caused intense pain in his calves when walking (claudication). This led to severe compensatory biomechanical shifts—he altered his gait, leading to chronic sacroiliac and lumbar facet pain. My role as his chiropractor was vital. By restoring normal pelvic alignment, mobilizing the lumbar spine, and utilizing soft tissue therapies on his lower extremities, we eliminated the secondary mechanical pain. This enabled him to successfully participate in a supervised physical therapy program utilizing a stationary bike to build cardiovascular collateral circulation.

At his one-year milestone, Amit had achieved a 16.3% reduction in total body weight. His HbA1c dropped to 6.0% (effectively reversing his type 2 diabetes requirement for insulin). Astonishingly, he had lost massive amounts of fat while actively increasing his skeletal muscle mass to the 25th percentile, successfully reversing his sarcopenia. His claudication pain nearly vanished, giving him a new lease on life.

Case Study 5: Osteoarthritis, Systemic Bias, and Surgical Preparation

Our final case highlights Dolores, a 72-year-old retired advisor whose dream of traveling was halted by severe, bone-on-bone osteoarthritis in her knees. Her orthopedic surgeon mandated that she lower her BMI below 40 before he would perform a bilateral total knee replacement.

The Intersecting Biases of Age, Gender, and Obesity

Dolores represents a demographic that suffers immense systemic bias in healthcare. Older women with obesity frequently have their complex metabolic struggles dismissed as “just getting older” or a lack of discipline. The requirement to lower BMI before joint surgery is a highly controversial, often arbitrary policy. It creates a cruel paradox: the patient is told to lose weight through exercise, but the agonizing joint destruction makes exercise impossible.

Dolores’s body composition revealed severe sarcopenia (muscle mass in the 2nd percentile). Her primary nutritional hurdle was a distaste for high-protein foods, and her psychological hurdle was an intense fear of physical therapy, rooted in past experiences of being shamed by fitness and medical professionals for her size.

Empathy, Advocacy, and Pharmacological Bridging

Our clinical pathway required as much psychological advocacy as it did metabolic science.

1. Empowerment and Coaching: I spent extensive time validating Dolores’s fears. We role-played conversations so she could assertively advocate for herself with her orthopedic surgeon and physical therapist. We sourced a compassionate, obesity-informed physical therapist who utilized an arm ergometer and seated resistance training to bypass her knee pain.
2. Pharmacotherapy with Naltrexone/Bupropion: To bridge the gap to surgery, Dr. Cardenas prescribed a combination of Naltrexone and Bupropion. This medication operates directly on the brain’s mesolimbic reward pathways. Bupropion increases dopamine and norepinephrine, enhancing metabolic rate and reducing depression, while Naltrexone (an opioid antagonist) blocks the endogenous opioid reward loop associated with eating hyper-palatable sweet foods. This effectively crushed her evening sugar cravings.
3. Surgical Coordination: Because Naltrexone blocks opioid receptors, it interferes with post-surgical pain medication. Dr. Cardenas masterfully coordinated the cessation of Naltrexone well before her first knee replacement, transitioning her to bupropion alone.
4. Transition to Semaglutide: Following a successful single knee replacement, Dolores’s mobility improved. To accelerate her progress toward her second surgery, we transitioned her to Semaglutide.

One year later, Dolores had reduced her body weight by 8.7%, normalized her fasting insulin, and increased her muscle mass to the 10th percentile. With one knee replaced and the other scheduled, her bags are packed for Europe. She overcame not only her metabolic dysfunction but the systemic biases that attempted to hold her back.

The Crucial Role of Integrative Chiropractic Care in Metabolic Health

Throughout these case studies, you will notice a recurring theme: chiropractic care is not an accessory to metabolic treatment; it is a fundamental pillar.

When a patient is suffering from Class II or Class III obesity, the mechanical load on the axial skeleton is immense. This alters spinal kinematics, strains the paraspinal musculature, and compresses nerve roots. This chronic, low-grade mechanical trauma generates a constant stream of nociceptive afferent signaling to the brain. The brain interprets this pain as a threat, locking the autonomic nervous system into a state of sympathetic dominance.

Sympathetic overdrive has catastrophic metabolic consequences. It elevates catecholamines (adrenaline) and cortisol. This hormonal cascade directly antagonizes insulin, raises blood pressure, and disrupts the deep, slow-wave sleep required for physical repair and appetite regulation.

By utilizing precise integrative chiropractic adjustments, soft-tissue myofascial release, and neurodynamic mobilizations, I effectively interrupt this nociceptive loop. As joint mechanics normalize, pain signaling decreases. Furthermore, by utilizing diaphragmatic breathing protocols and mobilizing the thoracic spine, we actively stimulate the vagus nerve, rapidly increasing parasympathetic tone.

This autonomic shift creates a physiological environment where healing can occur. It lowers cortisol, naturally improving insulin sensitivity. Most importantly, by eliminating pain, we restore movement capacity. The ability to engage in pain-free, consistent physical activity (like daily 10-minute walks) is the single most powerful driver of long-term weight maintenance and muscle preservation. Integrative chiropractic care makes the pharmacological and nutritional therapies exponentially more effective.

Ongoing Maintenance: The Architecture of Long-Term Health

The clinical strategies detailed above—whether it is GLP-1 therapy, transdermal MHT, high-protein macronutrient targeting, or neuromechanical adjustments—are not short-term fixes. They are interventions for a chronic disease. Therefore, maintenance is paramount.

Our long-term maintenance protocols at Injury Medical Clinic PA include:

• Vigilant Laboratory Monitoring: Regular tracking of HOMA-IR, A1c, advanced lipid panels, and liver enzymes by Dr. Cardenas to adjust pharmacotherapy as metabolic adaptation occurs.
• Body Composition Tracking: Ensuring that weight loss remains fat-centric while aggressively protecting and building skeletal muscle mass through periodized strength training.
• Nutritional Consistency: Maintaining a reduced-carbohydrate, high-protein environment to support gut-brain satiety signaling and stabilize glycemia.
• Chiropractic Maintenance: Periodic alignment and biomechanical tune-ups to prevent kinetic chain imbalances and protect joints from overuse injuries as activity levels increase.

Conclusion: A Vision for the Future of Healthcare

My extensive clinical observations, which you can review across my case logs at https://chiropracticscientist.com/ and my professional insights at https://www.linkedin.com/in/dralexjimenez/, consistently reinforce one undeniable truth: siloed healthcare is failing our patients.

We can no longer treat a patient’s knee pain without addressing the visceral fat driving their systemic inflammation. We cannot prescribe an obesity medication without ensuring the patient has the biomechanical capacity to build the muscle necessary to support their new metabolic rate. We cannot ignore the profound impact of perimenopausal hormone collapse on cardiovascular risk.

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), the collaboration between my integrative chiropractic and functional medicine expertise and the vast internal medicine oversight provided by Dr. Maria Guadalupe Cardenas, MD, represents the absolute gold standard of modern care. By synthesizing evidence-based pharmacology, advanced nutritional science, targeted physical rehabilitation, and compassionate behavioral advocacy, we do not just treat symptoms; we change biology, we restore dignity, and we rebuild lives.

References

• American College of Obstetricians and Gynecologists. (n.d.). Polycystic Ovary Syndrome: ACOG Practice Bulletin.
• American Diabetes Association. (2024). Standards of Medical Care in Diabetes.
• ACOG Committee Opinion. (2019). Contraception in women with metabolic disorders.
• Apovian, C. M., et al. (2015). Pharmacological management of obesity—An endocrine society guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Areta, J. L., et al. (2013). Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. The Journal of Physiology, 591(9), 2319–2331.
• Benite-Ribeiro, S. A., et al. (2011). AMPK signaling with short bouts of activity.
• Chavez, J. A., & Summers, S. A. (2012). Lipotoxicity and insulin resistance: The role of ceramides.
• Colberg, S. R., et al. (2010). Exercise and type 2 diabetes: ACSM/ADA joint position.
• DeFronzo, R. A., et al. (1995). Metformin’s mechanisms and clinical utility.
• DeFronzo, R. A., et al. (2021). Insulin resistance: a multifaceted syndrome.
• Eckel, R. H., et al. (2014). Cardiometabolic health: lifestyle-first strategies.
• Fairburn, C. G., et al. (1993). Binge eating disorder: diagnostic criteria and treatment approaches.
• Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515.
• Garber, C. E., et al. (2011). ACSM position stand on exercise quantity and quality.
• Garvey, W. T., et al. (2016). Guidelines for comprehensive medical care of patients with obesity. Endocrine Practice, 22(Suppl 3), 1–203.
• George, J. W., et al. (2019). Chiropractic care and autonomic modulation in pain.
• Green, B. D., et al. (2004). GLP-1 physiology and metabolic effects.
• Hales, C. M., et al. (2020). Prevalence of obesity and related cardiometabolic risks.
• Hall, K. D., et al. (2019). Ultra-processed foods and energy intake.
• Heymsfield, S. B., et al. (2014). Weight loss, lean mass, and metabolic rate.
• Hotamisligil, G. S. (2006). Inflammation in obesity and metabolic disease.
• Hudson, J. I., et al. (2015). Lisdexamfetamine for binge eating disorder: randomized trials.
• Jastreboff, A. M., et al. (2022). Tirzepatide for obesity and metabolic disease.
• Jensen, M. D., et al. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Journal of the American College of Cardiology, 63(25 Pt B), 2985–3023.
• Kahn, S. E., et al. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes.
• Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232.
• March, W. A., et al. (2010). PCOS prevalence and cardiometabolic risks.
• Mechanick, J. I., et al. (2013). Integration of nutrition and physical activity in obesity medicine.
• Mechanick, J. I., et al. (2020). Clinical practice guidelines for obesity and cardiometabolic disease.
• Mokdad, A. H., et al. (2003). The double burden of obesity and metabolic disease.
• Obesity Medicine Association. (2024). Obesity Algorithm and Clinical Practice Tools.
• Pagotto, U., et al. (2006). Endocannabinoid system and binge-like eating.
• Pont, S. J., et al. (2017). Binge eating disorder screening tools and validation.
• Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: a review and update. Obesity, 17(5), 941–964.
• Ramos, G. V., et al. (2016). Resistance training and metabolic health.
• Rosenfield, R. L., et al. (2013). Pathophysiology of PCOS and insulin resistance.
• Ross, R., et al. (2000). Physical activity and insulin sensitivity.
• Sacks, F. M., et al. (2009). Dietary composition and metabolic health.
• Schwartz, M. W., et al. (2000). Central regulation of appetite and energy balance.
• Sharma, A. M., & Kushner, R. F. (2009). Obesity staging and clinical decision-making.
• Shaw, K., et al. (2005). Psychological interventions for binge eating.
• Sumithran, P., et al. (2011). Hormonal adaptations to weight loss and implications for maintenance.
• The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.
• Verma, S., et al. (2022). GLP-1/GIP analogs: mechanisms and cardiometabolic impacts.
• Vinogradova, Y., et al. (2019). Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies. The BMJ, 367, l4212.
• Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.
• Wing, R. R., et al. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 34(7), 1481–1486.

SEO tags: integrative chiropractic care, obesity medicine, PCOS management, insulin resistance, tirzepatide, metformin, binge eating disorder, cardiometabolic risk reduction, functional medicine, rehabilitation, internal medicine collaboration, El Paso clinic, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas, reduced carbohydrate diet, autonomic regulation, diaphragmatic breathing, HOMA-IR improvement, fertility and obesity, women’s health, men’s health, evidence-based obesity treatment, GLP-1 semaglutide weight loss, appetite ghrelin leptin, CPAP sleep apnea metabolic health, perimenopause transdermal hormone therapy, resistance training preserve muscle, personal injury rehabilitation, stress management micro-practices, sarcopenic obesity, type 2 diabetes, cardiovascular disease, incretin mimetics, deprescribing insulin, peripheral artery disease, musculoskeletal support, weight bias, osteoarthritis, knee replacement, El Paso, TX